Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin.

Many of the therapeutic options available at the moment are characterized by need for hospitalization or repeated intravenous infusion, safety issues, possible drug-drug interactions and reduced efficacy on MDRs. Dalbavancin, the first long-acting molecule with strong activity against methicillin-resistant and also many vancomycin-resistant pathogens, represented a game changer for adult ABSSSI. In pediatric settings the available literature is still limited but a growing body of evidence supports dalbavancin use in children with ABSSSI, demonstrating this drug to be safe and highly efficacious.